Lupin Share Price Target 2025, 2030, 2040, 2050: Lupin Limited, one of India’s leading pharmaceutical companies, has a significant presence in the global market. Known for producing medicines at affordable prices, Lupin caters to various medical conditions including diabetes, heart problems, lung conditions, and mental health. With its well-established brand and diverse product portfolio, the company is poised for future growth. This article explores the expected share price targets for Lupin across multiple years and provides an analysis to help you make informed investment decisions.
Lupin Share Details
| Metric |
Value |
| Open Price |
₹1,956.05 |
| High Price |
₹2,012.00 |
| Low Price |
₹1,930.00 |
| Market Cap |
₹91.74K Cr |
| P/E Ratio |
31.89 |
| Dividend Yield |
0.40% |
| 52-Week High |
₹2,402.90 |
| 52-Week Low |
₹1,493.30 |
Lupin Share Price Target 2025, 2030, 2040, 2050
Lupin Share Price Target 2025 ₹3240, 2030 ₹6400, 2040 ₹8900, 2050 ₹14000. Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
- CEO: Vinita D. Gupta (Sept 2013–)
- Founder: Desh Bandhu Gupta
- Headquarters: Mumbai
- Number of employees: 19,210 (2024)
- Revenue: 16,715 crores INR (US$2.1 billion, 2023)
- Subsidiaries: Lupin Digital Health Ltd ·
Lupin Share Price Target 2025 To 2050
| Year |
Minimum Price (Rs) |
Maximum Price (Rs) |
| 2025 |
₹2200 |
₹3240 |
| 2030 |
₹5500 |
₹6400 |
| 2040 |
₹8100 |
₹8900 |
| 2050 |
₹12200 |
₹14000 |
Category: Stock Market
What is Lupin Ltd?
Lupin Limited is a renowned pharmaceutical company based in India. It manufactures a wide range of products including biosimilars, generic drugs, and over-the-counter (OTC) medications. The company operates in over 100 countries including the United States, India, South Africa, various regions in Asia, Latin America, Europe, and the Middle East. Lupin’s product offerings include medicines for diabetes, heart disease, respiratory issues, infections, gastrointestinal problems, and mental health disorders. Founded in 1968 by Desh Bandhu Gupta, Lupin has steadily expanded its footprint in the global pharmaceutical market.
Lupin Share Price Target for 2025
Lupin’s fundamentals are strong, with a low debt-to-equity ratio of 0.20. Its market capitalization and performance in recent years are impressive. Analysts predict that the stock will continue to perform well in the coming year, with an expected price target of ₹3240.
Expected Range for 2025: ₹2200 to ₹3240
| Year |
Minimum Price (Rs) |
Maximum Price (Rs) |
| 2025 |
₹2200 |
₹3240 |
Month Wise Lupin Share Price Target 2025
| Month |
Minimum Price (Rs) |
Maximum Price (Rs) |
| January |
₹2276 |
₹2784 |
| February |
₹2213 |
₹2760 |
| March |
₹2250 |
₹2790 |
| April |
₹2200 |
₹2848 |
| May |
₹2230 |
₹2860 |
| June |
₹2257 |
₹2895 |
| July |
₹2290 |
₹2964 |
| August |
₹2327 |
₹2980 |
| September |
₹2300 |
₹3057 |
| October |
₹2376 |
₹3122 |
| November |
₹2350 |
₹3130 |
| December |
₹2413 |
₹3240 |
Also Check:
Jindal SAW Share Price Target
Paytm Share Price Target
Berger Paints Share Price Target
Lupin Share Price Target for 2030
Lupin has experienced rapid growth in India, thanks to its affordable and effective medicines, particularly in the heart medicine segment. The company has expanded to over 70 countries and built a strong brand reputation. Despite the fluctuations in its stock price, long-term investors have seen good returns. For the year 2030, Lupin’s share price target is expected to reach ₹6400.
Expected Range for 2030: ₹5500 to ₹6400
| Year |
Minimum Price (Rs) |
Maximum Price (Rs) |
| 2030 |
₹5500 |
₹6400 |
Month Wise Lupin Share Price Target 2030
| Month |
Minimum Price (Rs) |
Maximum Price (Rs) |
| January |
₹5500 |
₹5631 |
| February |
₹5567 |
₹5670 |
| March |
₹5600 |
₹5700 |
| April |
₹5550 |
₹5760 |
| May |
₹5640 |
₹5800 |
| June |
₹5700 |
₹5930 |
| July |
₹5840 |
₹5900 |
| August |
₹5890 |
₹6100 |
| September |
₹5940 |
₹6173 |
| October |
₹6000 |
₹6250 |
| November |
₹6123 |
₹6300 |
| December |
₹6280 |
₹6400 |
Lupin Share Price Target for 2040
As India’s population continues to grow and the demand for medicines increases, Lupin is well-positioned to capitalize on these trends. The company is expanding its production and operations to meet the rising demand. If the company continues on its current growth trajectory, analysts predict a price target of ₹8900 for the year 2040.
Expected Range for 2040: ₹8100 to ₹8900
| Year |
Minimum Price (Rs) |
Maximum Price (Rs) |
| 2040 |
₹8100 |
₹8900 |
Month Wise Lupin Share Price Target 2040
| Month |
Minimum Price (Rs) |
Maximum Price (Rs) |
| January |
₹8100 |
₹8230 |
| February |
₹8185 |
₹8280 |
| March |
₹8200 |
₹8346 |
| April |
₹8267 |
₹8350 |
| May |
₹8290 |
₹8400 |
| June |
₹8330 |
₹8450 |
| July |
₹8300 |
₹8570 |
| August |
₹8450 |
₹8683 |
| September |
₹8546 |
₹8712 |
| October |
₹8621 |
₹8767 |
| November |
₹8715 |
₹8780 |
| December |
₹8825 |
₹8900 |
Lupin Share Price Target for 2050
Lupin is a trusted global brand, well-known for its quality medicines that cater to significant diseases such as heart conditions, diabetes, and mental health. As the company continues to strengthen its position both in India and abroad, its stock price is projected to reach ₹14000 by 2050, reflecting its sustained growth.
Expected Range for 2050: ₹12200 to ₹14000
| Year |
Minimum Price (Rs) |
Maximum Price (Rs) |
| 2050 |
₹12200 |
₹14000 |
Month Wise Lupin Share Price Target 2050
| Month |
Minimum Price (Rs) |
Maximum Price (Rs) |
| January |
₹12200 |
₹12357 |
| February |
₹12270 |
₹12442 |
| March |
₹12340 |
₹12530 |
| April |
₹12400 |
₹12631 |
| May |
₹12540 |
₹12738 |
| June |
₹12609 |
₹12900 |
| July |
₹12690 |
₹13030 |
| August |
₹12875 |
₹13100 |
| September |
₹13056 |
₹13360 |
| October |
₹13400 |
₹13625 |
| November |
₹13600 |
₹13831 |
| December |
₹13780 |
₹14000 |
Should I Buy Lupin Stock?
Lupin stock is gaining popularity among investors due to its strong fundamentals and consistent performance. Below is a summary of the share price targets for Lupin over the next several years. Lupin’s best-selling products include medications for diabetes, infections, heart disease, and asthma, along with popular brand-name drugs such as Lupitac, Metoject, and Lupizole. If you’re considering investing in a pharmaceutical company, Lupin stock is worth evaluating, especially given its recent growth of over 100% in the past year, which has provided investors with excellent returns.
Bull Case & Bear Case
Bull Case
- Lupin is expanding globally with new medicines and improved sales.
- The company’s consistent sales growth and rising profits suggest a positive future.
- The increasing global demand for generic drugs benefits Lupin, a major player in this segment.
Bear Case
- Regulatory challenges in different countries could lead to fines or bans.
- Intense competition in the pharmaceutical industry could impact market share.
What does the company Lupin do?
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
Who is the CEO of Lupin?
Vinita Gupta | Chief Executive Officer – Lupin.
What is the salary of Lupin CEO?
In 2024, Vinita Gupta, the CEO of Lupin Ltd., had a gross remuneration of ₹23.56 crore.
Is Lupin a good company?
Is Lupin a good company to work for? Lupin has an overall rating of 3.8 out of 5, based on over 1,128 reviews left anonymously by employees. 75% of employees would recommend working at Lupin to a friend and 74% have a positive outlook for the business. This rating has been stable over the past 12 months.
